FDA Seeks More Data on Blood Cancer Drug

U.S. drug regulators completed their review of a blood cancer drug from Spectrum Pharmaceuticals(SPPI Quote) Friday but delayed approval until the company submitted more data.

Spectrum said it plans to respond to the Food and Drug Administration request by Wednesday, but final approval of its drug Zevalin probably will be delayed by two months.

"This is clearly not the result we were looking for, but we're still very confident about [Zevalin's] approval," said Spectrum spokesman Paul Arndt, in an interview Sunday night. ...